Chapter 3

References

  1. LaFreniere M, Hussain H, He N, McGuire Tuberculosis in Canada: 2017. Can Commun Dis Rep. 2019;45(2-3):67–74. doi:10.14745/ ccdr.v45i23a04.
  2. Daley CL, Gotway MB, Jasmer Radiographic Manifestations of Tuberculosis: A Primer for Clinicians. Francis J. Curry National Tuberculosis Center San Francisco; 2003.
  3. Benito N, Garcia-Vazquez E, Horcajada JP, et al. Clinical features and outcomes of tuberculosis in transplant recipients as compared with the general population: a retrospective matched cohortClin Microbiol Infect. 2015;21(7):651–658. doi:10.1016/j.cmi.2015.03.010.
  4. Heffernan C, Barrie J, Doroshenko A, et Prompt recognition of infectious pulmonary tuberculosis is critical to achieving elim- ination goals: a retrospective cohort study. BMJ Open Resp Res.2020;7(1):e000521. doi:10.1136/bmjresp-2019-000521.
  5. Bailey WC, Gerald LB, Kimerling ME, et Predictive model to identify positive tuberculosis skin test results during contact investigations. JAMA.  2002;287(8):996–1002.  doi:10.1001/jama.287.8.996.
  6. Catanzaro A. Nosocomial tuberculosis. Am Rev Respir Dis. 1982;125(5):559–562. doi:1164/arrd.1982.125.5.559.
  7. Golub JE, Bur S, Cronin WA, et al. Delayed tuberculosis diag- nosis and tuberculosis transmission. Int J Tuberc Lung Dis. 2006;10(1):24–30.
  8. Bumbacea D, Arend SM, Eyuboglu F, et al. The risk of tuber- culosis in transplant candidates and recipients: a TBNET con- sensus   Eur  Respir  J.  2012;40(4):990–1013. doi:10.1183/09031936.00000712.
  9. Fang HC, Lee PT, Chen CL, Wu MJ, Chou KJ, Chung HM. Tuberculosis in patients with end-stage renal disease. Int J Tuberc Lung Dis. 2004;8(1):92–97.
  10. Andrew OT, Schoenfeld PY, Hopewell PC, Humphreys MH. Tuberculosis in patients with end-stage renal disease. Am J Med. 1980;68(1):59–65. doi:1016/0002-9343(80)90166-7.
  11. Iclal I, Bilge BF, Fusun K, Galip Pleuropulmonary tubercu- losis in patients with end-stage renal disease: findings on chest radiographs. Transplant Proc. 1999;31(3):1719–1720. doi:10.1016/S0041-1345(99)00076-7.
  12. Toman K. Tuberculosis Case-Finding and Chemotherapy. Geneva, Switzerland: World Health Organization;
  13. Yeh JJ, Yu JK, Teng WB, et al. High-resolution CT for identify patients with smear-positive, active pulmonary Eur J Radiol. 2012;81(1):195–201. doi:10.1016/j.ejrad.2010.09.040.
  14. Im JG, Itoh H, Shim YS, et al. Pulmonary tuberculosis: CT findings–early active disease and sequential change with antitu- berculous Radiology. 1993;186(3):653–660. doi:10.1148/radiology.186.3.8430169.
  15. Matsuoka S, Uchiyama K, Shima H, et Relationship between CT findings of pulmonary tuberculosis and the number of acid-fast bacilli on sputum smears. Clin Imaging. 2004;28(2):119– doi:10.1016/S0899-7071(03)00148-7.
  16. Ors F, Deniz O, Bozlar U, et al. High-resolution CT findings in patients with pulmonary tuberculosis: correlation with the degree of smear J Thorac Imaging. 2007;22(2):154–159.doi:10.1097/01.rti.0000213590.29472.ce.
  17. Yeh JJ, Neoh CA, Chen CR, Chou CY, Wu MT. A high resolution computer tomography scoring system to predict culture-positive pulmonary tuberculosis in the emergency department. PLoS One. 2014;9(4):e93847. doi:10.1371/journal.pone.0093847.
  18. Nakanishi M, Demura Y, Ameshima S, et Utility of high-resolution computed tomography for predicting risk of spu- tum smear-negative pulmonary tuberculosis. Eur J Radiol. 2010;73(3):545–550. doi:10.1016/j.ejrad.2008.12.009.
  19. Rizzi EB, Schinina V, Cristofaro M, et al. Detection of Pulmonary tuberculosis: comparing MR imaging with BMC Infect Dis. 2011;11:243. doi:10.1186/1471-2334-11-243.
  20. Yu WY, Lu PX, Assadi M, et Updates on (18)F-FDG-PET/ CT as a clinical tool for tuberculosis evaluation and therapeutic monitoring. Quant Imaging Med Surg. 2019;9(6):1132–1146. doi:10.21037/qims.2019.05.24.
  21. Geadas C, Acuna-Villaorduna C, Mercier G, et al. FDG-PET/CT activity leads to the diagnosis of unsuspected TB: a retrospective BMC Res Notes. 2018;11(1):464. doi:10.1186/s13104-018-3564-6.
  22. Murphy K, Habib SS, Zaidi SMA, et Computer aided detec- tion of tuberculosis on chest radiographs: An evaluation of the CAD4TB v6 system. Sci Rep. 2020;10(1):5492. doi:10.1038/s41598-020-62148-y.
  23. World Health Organization. Rapid Communication on Systematic Screening for Tuberculosis. Geneva. 2020. Licence: CC BY-NC-SA 3.0 IGO. Web site: https://www.who.int/publications/i/item/ rapid-communication-on-the-systematic-screening-fo r-tuberculosis. Accessed February 26, 2022.
  24. Khan FA, Majidulla A, Tavaziva G, et Chest x-ray analysis with deep learning-based software as a triage test for pulmonary tuberculosis: a prospective study of diagnostic accuracy for culture-confirmed disease. Lancet Digit Health. 2020;2(11):e573–e581. doi:10.1016/S2589-7500(20)30221-1.
  25. Heffernan C, Rowe BH, Long Engaging frontline providers: an important key to eliminating tuberculosis in Canada, andother high-income countries. Can J Public Health. 2021;112(5):872– 876. doi:10.17269/s41997-021-00556-x.
  26. Lewinsohn DM, Leonard MK, LoBue PA, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clin Infect Dis. 2017;64(2):111–115. doi:10.1093/cid/ciw778.
  27. Woods GL, Brown-Elliott BA, Conville PS, et al. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic 2nd ed. https://clsi.org/media/1463/m24a2_sample.pdf. Wayne (PA); 2011. Clinical and Laboratory Standards Institute. Accessed February 26, 2022.
  28. Association of Public Health Labratories. Mycobacterium tuber- culosis:Assessing Your Laboratory.
  29. Menzies D, Gonzalo G, Khan K, Public Health Agency of Canada. In: Canadian Tuberculosis Standard, chap 6: Treatment of Latent Tuberculosis Infection, 7th ed. Can Respir J. 2013;20(Suppl A).
  30. Mase SR, Ramsay A, Ng V, et al. Yield of serial sputum specimen examinations in the diagnosis of pulmonary tuberculosis: a sys- tematic Int J Tuberc Lung Dis. 2007;11(5):485–495.
  31. Monkongdee P, McCarthy KD, Cain KP, et al. Yield of acid-fast smear and mycobacterial culture for tuberculosis diagnosis in people with human immunodeficiency virus. Am J Respir Crit Care Med. 2009;180(9):903–908. doi:10.1164/rccm.200905-0692OC.
  32. Harvell JD, Hadley WK, Ng VL. Increased sensitivity of the BACTEC 460 mycobacterial radiometric broth culture system does not decrease the number of respiratory specimens required for a definitive diagnosis of pulmonary tuberculosis. J Clin Microbiol. 2000;38(10):3608–3611. doi:10.1128/JCM.38.10.3608-3611.2000.
  33. Davis JL, Cattamanchi A, Cuevas LE, Hopewell PC, Steingart Diagnostic accuracy of same-day microscopy versus standard microscopy for pulmonary tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13(2):147–154. doi:10.1016/S1473-3099(12)70232-3.
  34. Hepple P, Ford N, McNerney R. Microscopy compared to culture for the diagnosis of tuberculosis in induced sputum samples: a systematic Int j Tuberc Lung Dis. 2012;16(5):579–588. doi:10.5588/ijtld.11.0617.
  35. Menzies D, Khan K. Canadian Tuberculosis Standards, 6th ed. Ottawa: Canadian Lung Association, Public Health Agency of Canada, Tuberculosis Prevention and Control; 2007.
  36. Anderson C, Inhaber N, Menzies D. Comparison of sputum induction with fiber-optic bronchoscopy in the diagnosis of tu- Am J Respir Crit Care Med. 1995;152(5):1570–1574. doi:10.1164/ajrccm.152.5.7582296.
  37. Zar HJ, Tannenbaum E, Apolles P, Roux P, Hanslo D, Hussey G. Sputum induction for the diagnosis of pulmonary tuberculosis in infants and young children in an urban setting in South Africa. Arch Dis Child. 2000;82(4):305–308. doi:10.1136/adc.82.4.305.
  38. American Thoracic Society. Diagnostic standards and classifica- tion of Am Rev Respir Dis. 1990;142(3):725–735.
  39. Chawla R, Pant K, Jaggi OP, Chandrashekhar S, Thukral SS. Fibreoptic bronchoscopy in smear-negative pulmonary tubercu- Eur Respir J. 1988;1(9):804–806.
  40. So SY, Lam WK, Yu DY. Rapid diagnosis of suspected pulmonary tuberculosis by fiberoptic bronchoscopy. Tubercle. 1982;63(3):195– doi:10.1016/S0041-3879(82)80030-5.
  41. Wallace JM, Deutsch AL, Harrell JH, Moser KM. Bronchoscopy and transbronchial biopsy in evaluation of patients with suspect- ed active Am J Med. 1981;70(6):1189–1194. doi:10.1016/0002-9343(81)90826-3.
  42. Chan HS, Sun AJ, Hoheisel GB. Bronchoscopic aspiration and bronchoalveolar lavage in the diagnosis of sputum smear-negative pulmonary Lung. 1990;168(1):215–220. doi:10.1007/BF02719695.
  43. Bahammam A, Choudhri S, Long Utility of gastric aspirates in screening for pulmonary tuberculosis in high risk subjects:The Manitoba experience. Can J Infect Dis. 1999;10(1):69–73.
  44. Walters E, Demers AM, van der Zalm MM, et Stool Culture for Diagnosis of Pulmonary Tuberculosis in Children. J Clin Microbiol. 2017;55(12):3355–3365. doi:10.1128/JCM.00801-17.
  45. Yeager H, Lacy J, Smith LR, LeMaistre Quantitative studies of mycobacterial populations in sputum and saliva. Am Rev Respir Dis. 1967;95(6):998–1004. doi:10.1164/arrd.1967.95.6.998.
  46. Hobby GL, Holman AP, Iseman MD, Jones JM. Enumeration of tubercle bacilli in sputum of patients with pulmonary tubercu- Antimicrob Agents Chemother. 1973;4(2):94–104. doi:10.1128/AAC.4.2.94.
  47. Behr MA, Warren SA, Salamon H, et al. Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast Lancet (London, England). 1999;353(9151):444– doi:10.1016/S0140-6736(98)03406-0.
  48. Global Laboratory  Initiative  WHO  Stop  TB Mycobacteriology laboratory manual. 2014.
  49. Ling DI, Flores LL, Riley LW, Pai M. Commercial nucleic-acid amplification tests for diagnosis of pulmonary tuberculosis in respiratory specimens: meta-analysis and meta-regression. PLoS One. 2008;3(2):e1536. doi:10.1371/journal.pone.0001536.
  50. Flores LL, Pai M, Colford JM, Jr., Riley LW. In-house nucleic acid amplification tests for the detection of Mycobacterium tuberculosis in sputum specimens: meta-analysis and meta-regression. BMC Microbiol. 2005;5:55. doi:10.1186/1471-2180-5-55.
  51. Sarmiento OL, Weigle KA, Alexander J, Weber DJ, Miller WC. Assessment by meta-analysis of PCR for diagnosis of smear-negative pulmonary    J  Clin  Microbiol. 2003;41(7):3233–3240. doi:10.1128/JCM.41.7.3233-3240.2003.
  52. Zifodya JS, Kreniske JS, Schiller I, et al. Xpert Ultra versus Xpert MTB/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary Cochrane Database Syst Rev. 2021;2:CD009593. doi:10.1002/14651858.CD009593.pub5.
  53. World Health Organization. WHO meeting report of a technical expert consultation: non-inferiority analysis of Xpert MTB/RIF Ultra compared to Xpert MTB/RIF.
  54. Nathavitharana RR, Cudahy PG, Schumacher SG, Steingart KR, Pai M, Denkinger CM. Accuracy of line probe assays for the diagnosis of pulmonary and multidrug-resistant tuberculosis: a systematic  review  and  meta-analysis.  Eur  Respir  J. 2017;49(1):1601075. doi:10.1183/13993003.01075-2016.
  55. Steingart KR, Flores LL, Dendukuri N, et al. Commercial sero- logical tests for the diagnosis of active pulmonary and extrapul- monary tuberculosis:  an  updated  systematic  review  and meta-analysis. PLoS Med. 2011;8(8):e1001062. doi:10.1371/journal.pmed.1001062.
  56. Dowdy DW, Steingart KR, Pai Serological testing versus other strategies for diagnosis of active tuberculosis in India: a cost-effectiveness analysis.  PLoS  Med.  2011;8(8):e1001074. doi:10.1371/journal.pmed.1001074.
  57. Morris K. WHO recommends against inaccurate tuberculosis Lancet. 2011;377(9760):113–114. doi:10.1016/ S0140-6736(11)60005-6.
  58. World Health Organization. WHO Operational Handbook on Module 3: diagnosis—Rapid Diagnostics for Tuberculosis Detection 2021 Update. https://www.who.int/publi- cations/i/item/9789240030589. 2021. Licence: CC BY-NC-SA 3.0 IGO. Accessed February 26, 2022.
  59. Aggarwal AN, Agarwal R, Sehgal IS, Dhooria S. Adenosine de- aminase for diagnosis of tuberculous pleural effusion: A system- atic review and meta-analysis. PLoS One. 2019;14(3):e0213728. doi:10.1371/journal.pone.0213728.
  60. Bulterys MA, Wagner B, Redard-Jacot M, et al. Point-Of-Care Urine LAM Tests for Tuberculosis Diagnosis: A Status J Clin Med. 2019;9(1):111.
  61. Forbes BA, Hall GS, Miller MB, et al. Practical Guidance for Clinical Microbiology Laboratories: Mycobacteria. Clin Microbiol Rev. 2018;31(2):e00038-17. doi:1128/CMR.00038-17.
  62. Government of Human Pathogens and Toxins Regulations. 2015.
  63. Government of Canadian Biosafety Standard (CBS), 2nd ed. 2015. https://www.canada.ca/en/public-health/services/ canadian-biosafety-standards-guidelines/second-edition.html. Accessed on February 26, 2022.
  64. Public Health Agency of Canada. Biosafety Directive for Mycobacterium tuberculosis Complex (MTBC).
  65. Transport Canada. Transportation of dangerous goods in Canada. AEAD 17002250 Web site. https://tc.canada.ca/en/dangerous-goods/ transportation-dangerous-goods-canada. Published 2021. Accessed February 26, 2022.
  66. Steingart KR, Henry M, Ng V, et al. Fluorescence versus con- ventional sputum smear microscopy for tuberculosis: a system- atic Lancet Infect Dis. 2006;6(9):570–581. doi:10.1016/S1473-3099(06)70578-3.
  67. Steingart KR, Ramsay A, Pai M. Optimizing sputum smear mi- croscopy for the diagnosis of pulmonary tuberculosis. Expert Rev anti Infect Ther. 2007;5(3):327–331. doi:1586/14787210.5.3.327.
  68. Steingart KR, Ng V, Henry M, et Sputum processing methods to improve the sensitivity of smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis. 2006;6(10):664–674.doi:10.1016/S1473-3099(06)70602-8.
  69. Salfinger M, Pfyffer GE. The new diagnostic mycobacteriology Eur J Clin Microbiol Infect Dis. 1994;13(11):961–979. doi:10.1007/BF02111498.
  70. Clinical and Laboratory Standards Institute. Laboratory Detection and Identification of Clsi Guideline M48 2018. M48.
  71. Association of Public Health Laboratories. AFB Smear Microscopy. https://www.aphl.org/programs/infectious_disease/tuberculosis/ TBCore/TB_AFB_Smear_Microscopy_TrainerNotes.pdf. Accessed February 26,
  72. Health Canada. Medical Devices Active Licence Listing. https:// health-products.canada.ca/mdall-limh/prepareSearch- do?type=archived_archive. Published 2012. Updated 2021. Accessed.
  73. Steingart KR, Sohn H, Schiller I, et Xpert(R) MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. 2014;2014(1):CD009593.
  74. Boehme CC, Nicol MP, Nabeta P, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance:  a  multicentre  implementation  study.  Lancet. 2011;377(9776):1495–1505. doi:10.1016/S0140-6736(11)60438-8.
  75. Tortoli E, Cichero P, Piersimoni C, Simonetti MT, Gesu G, Nista D. Use of BACTEC MGIT 960 for recovery of mycobacteria from clinical specimens: multicenter study. J Clin Microbiol. 1999;37(11):3578–3582. doi:10.1128/JCM.37.11.3578-3582.1999.
  76. Clinical and Laboratory Standards Institute. Molecular Diagnostic Methods for Infectious Diseases. 3rd Edition. 2015. https://clsi. org/standards/products/molecular-diagnostics/documents/mm03/. Accessed August 8, 2021.
  77. Clinical and Laboratory Standards Institute. MM09-A2: Nucleic Acid Sequencing Methods in Diagnostic Labratory Medicine; Approved Guideline, 2nd ed.; 2004. https://clsi.org/standards/ products/molecular-diagnostics/documents/mm09/. Accessed August 8, 2021.
  78. Al Zahrani K, Al Jahdali H, Poirier L, Rene P, Menzies Yield of smear, culture and amplification tests from repeated sputum induction for the diagnosis of pulmonary tuberculosis. Int J Tuberc Lung Dis. 2001;5(9):855–860.
  79. Heifets LB, Desmond Clinical Mycobacteriology (Tuberculosis) Laboratory: Services and Methods. In: Cole S, Eisenach K, McMurray D, Jacobs W, eds. Tuberculosis and the Tubercle Bacillus. Washington DC: ASM press; 2005. 49–69.
  80. Burman WJ, Stone BL, Reves RR, et The incidence of false-positive cultures for Mycobacterium tuberculosis. Am J Respir Crit Care Med. 1997;155(1):321–326. doi:10.1164/ajrccm.155.1.9001331.
  81. Ruddy M, McHugh TD, Dale JW, et Estimation of the rate of unrecognized cross-contamination with mycobacterium tuber- culosis in London microbiology laboratories. J Clin Microbiol. 2002;40(11):4100–4104. doi:10.1128/JCM.40.11.4100-4104.2002.
  82. Small PM, McClenny NB, Singh SP, Schoolnik GK, Tompkins LS, Mickelsen PA. Molecular strain typing of Mycobacterium tuberculosis to confirm cross-contamination in the mycobacteriology laboratory and modification of procedures to minimize occurrence of false-positive cultures. J Clin Microbiol. 1993;31(7):1677–1682. doi:10.1128/jcm.31.7.1677-1682.1993.
  83. Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. Am J Respir Crit Care Med. 2000;161(4 Pt 1):1376–1395.
  84. Clinical and Laboratory Standards Institute. Susceptibility Testing of Mycobacteria, Nocardia Spp., and Other Aerobic Actinomycetes. 3rd ; 2018. https://clsi.org/media/2620/m24ed3_sample.pdf. Accessed February 26, 2022.
  85. Danchuk SN, McIntosh F, Jamieson FB, May K, Behr Bacillus Calmette-Guerin strains with defined resistance muta- tions: a new tool for tuberculosis laboratory quality control. Clin Microbiol Infect. 2020;26(3):384 e385–384 e388.
  86. Penn-Nicholson A, Georghiou SB, Ciobanu N, et Detection of isoniazid, fluoroquinolone, ethionamide, amikacin, kanamycin, and capreomycin resistance by the Xpert MTB/XDR assay: a cross-sectional multicentre diagnostic accuracy study. Lancet Infect Dis. 2021; 22(2):242–249.
  87. Ling DI, Zwerling AA, Pai M. GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis. Eur Respir  J.  2008;32(5):1165–1174.  doi:1183/09031936.00061808.
  88. Meehan CJ, Goig GA, Kohl TA, et Whole genome sequenc- ing of Mycobacterium tuberculosis: current standards and open issues. Nat Rev Microbiol. 2019;17(9):533–545. doi:10.1038/s41579-019-0214-5.
  89. CRyPTIC Consortium and the 100 GP. Prediction of suscepti- bility to first-line tuberculosis drugs by DNA New Eng J Med. 2018;379(15):1403–1415.
  90. Jajou R, van der Laan T, de Zwaan R, et WGS more accu- rately predicts susceptibility of Mycobacterium tuberculosis to first-line drugs than phenotypic testing. J Antimicrob Chemother. 2019;74(9):2605–2616. doi:10.1093/jac/dkz215.
  91. Shea J, Halse TA, Lapierre P, et al. Comprehensive Whole-Genome Sequencing and Reporting of Drug Resistance Profiles on Clinical Cases of Mycobacterium tuberculosis in New York State.  J  Clin  Microbiol.  2017;55(6):1871–1882.  doi:10.1128/JCM.00298-17.
  92. Brown AC, Bryant JM, Einer-Jensen K, et Rapid Whole-Genome Sequencing of Mycobacterium tuberculosis Isolates Directly from Clinical Samples. J Clin Microbiol. 2015;53(7):2230–2237. doi:10.1128/JCM.00486-15.
  93. Votintseva AA, Bradley P, Pankhurst L, et Same-Day Diagnostic and Surveillance Data for Tuberculosis via Whole-Genome Sequencing of Direct Respiratory Samples. J Clin  Microbiol .  2017;55(5):1285–1298.  doi: 10.1128/JCM.02483-16.
  94. Doberne D, Gaur RL, Banaei N. Preanalytical delay reduces sensitivity of QuantiFERON-TB gold in-tube assay for detec- tion of  latent  tuberculosis    J  Clin  Microbiol. 2011;49(8):3061–3064.   doi:10.1128/JCM.01136-11.
  95. Herrera V, Yeh E, Murphy K, Parsonnet J, Banaei N. Immediate incubation reduces indeterminate results for QuantiFERON-TB Gold in-tube J Clin Microbiol. 2010;48(8):2672–2676. doi:10.1128/JCM.00482-10.
  96. Oxford Immunotec. T-SPOT. TB package insert PI- TB8-IVD- UK-V4.
  97. Oxford Immunotec. T-SPOT. TB training guide, TH- TB- UK-V3 http://www.oxfordimmunotec.com/north-america/wp-content/ uploads/sites/2/TG-TB-US-V5.pdf. Published 2012. Accessed February 26, 2022.
  98. Oxford Immunotec. TB T-Cell Xtend package insert, PI-TT.610- US-V4 https://www.tspot.com/resources/resource/t-cell- xtend-package-insert/. Published 2012. Accessed February 26,

Switch To: Français

Previously
Funding
Up Next
Appendix 1. Tuberculosis and mycobacteriology laboratory standards: Services and policies